Patient characteristics
| Characteristic . | n = 30 . |
|---|---|
| Male sex, n (%) | 12 (40) |
| Age, median (range), y | 33 (18-69) |
| Stage, n (%) | |
| I | 1 (3) |
| II | 11 (37) |
| III | 7 (23) |
| IV | 11 (37) |
| B symptoms, n (%) | 13 (43) |
| Mediastinal bulk, >10 cm, n (%) | 6 (20) |
| Elevated erythrocyte sedimentation rate, >50, n (%) | 11 (37) |
| Extranodal involvement, n (%) | 11 (37) |
| Spleen involvement, n (%) | 7 (23) |
| Early-stage unfavorable, National Comprehensive Cancer Network (n = 12), n (%) | 6 (50) |
| International Prognostic Score (advanced stage, n = 18), n (%) | |
| 0-1 | 6 (33) |
| 2 and 3 | 7 (39) |
| 4, 5, 6, and 7 | 5 (28) |
| Characteristic . | n = 30 . |
|---|---|
| Male sex, n (%) | 12 (40) |
| Age, median (range), y | 33 (18-69) |
| Stage, n (%) | |
| I | 1 (3) |
| II | 11 (37) |
| III | 7 (23) |
| IV | 11 (37) |
| B symptoms, n (%) | 13 (43) |
| Mediastinal bulk, >10 cm, n (%) | 6 (20) |
| Elevated erythrocyte sedimentation rate, >50, n (%) | 11 (37) |
| Extranodal involvement, n (%) | 11 (37) |
| Spleen involvement, n (%) | 7 (23) |
| Early-stage unfavorable, National Comprehensive Cancer Network (n = 12), n (%) | 6 (50) |
| International Prognostic Score (advanced stage, n = 18), n (%) | |
| 0-1 | 6 (33) |
| 2 and 3 | 7 (39) |
| 4, 5, 6, and 7 | 5 (28) |